Navigation Links
SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
Date:7/26/2011

BOTHELL, Wash., July 26, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today reported financial results for the three months and six months ended June 30, 2011 and also provided updates on a number of key corporate objectives.

As previously announced, the Company issued an aggregate of $1.2 million principal amount of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures") in a private offering of Debentures. The Company intends to utilize the net proceeds of the offering for working capital and other general corporate purposes.  

Stephen Turner, President and CEO, said: "We believe we are poised to have a successful nutritional products business. Retailers with whom we have met have conveyed enthusiasm about our extended release nutritionals."  

Turner added: "We are pleased with the positive response that we had to our offering and the continued support of our shareholders. With the positive support from the retailers and the additional capital from this offering, we are positioned to meet the needs and demands of retailers for our nutritional products."

Second Quarter 2011 compared to Second Quarter 2010 Financial ResultsTotal revenues for the quarter ended June 30, 2011 were $8,000, a 96% decrease, compared to $223,000 for the same period in 2010. This decrease is due to a $115,000 reduction in royalty revenue from sales of SCOLR nutritional products by Perrigo Company. The Company receives royalty payments based on Perrigo's net profits from the sales of products subject to a license agreement between the companies.  As previously reported, during the fourth quarter of 2010 SCOLR was informed by Perrigo that some retail accounts will no longer carry certain Perrigo products.  The revenues from Perrigo decreased substantially as a result of such discontinuance as remaining product was sold, and the Company expects the revenues from Perrigo to be negligible for the remainder of 2011.

For the quarter ended June 30, 2011, the Company's marketing and selling expenses decreased 38%, or $33,000, to $53,000, compared to $86,000 for the same period in 2010.  This decrease was primarily due to a reduction in sales commissions and royalties due to lower royalty revenues.

The Company recorded a gain of $103,000 on research and development activity compared to an expense of $256,000 for the same period in 2010.  The gain was a result of receiving proceeds during the quarter on sale of certain laboratory equipment of $120,000, combined with lower research and development expenses following the elimination of its laboratory activities.

General and administrative expenses increased 2%, or $13,000, to $585,000 for the three months ended June 30, 2011, compared to approximately $572,000 for the same period in 2010.   The increase was primarily due to recognition of $61,000 in accelerated depreciation expense related to leasehold improvements as a result of a reduction in the term of our headquarters lease. This increase was offset by a decrease in office expense.

Other income decreased 106%, or $222,000, to an expense of $12,000 for the three months ended June 30, 2011, compared to income of $210,000 for the comparable period in 2010. This decrease is due to a change in unrealized gain (loss) on the fair value of a warrant to purchase common stock.  

Net loss increased 12%, or $58,000, to $539,000 for the three months ended June 30, 2011, compared to $481,000 for the same period in 2010. The increase in net loss reflects lower revenues and the change in the unrealized gain (loss) on fair value of warrant to purchase common stock.

Comparison of the Year to Date Six Months Ended June 30, 2011 and 2010 Total revenues, which consist of licensing fees, research and development revenues, and royalty revenue from SCOLR's collaboration agreements, decreased 51%, or $197,000, to $192,000 for the six months ended June 30, 2011, compared to $389,000 for the same period in 2010. This decrease is due to a $190,000 reduction in royalty revenue from sales of nutritional products by Perrigo compared to the prior period. The Company recognized $100,000 in research and development revenue attributable to a contract with RedHill Biopharma Ltd. for certain development services in connection with the license by RedHill of SCOLR's CDT platforms for use in Ondansetron tablet formulations, as well as an $18,000 research and development from Syntrix Biopharma.

Marketing and selling expenses increased 23%, or $33,000, to $178,000 for the six months ended June 30, 2011, compared to $145,000 for the same period in 2010. This increase was primarily due to marketing and sales brokerage related expenses and the addition of a sales and marketing staff person anticipated to assist with advancement of our of nutritional products business.

Research and development expenses decreased 9%, or $52,000, to $544,000 for the six months ended June 30, 2011, compared to $596,000 for the same period in 2010. This decrease is due to the gain on sale of lab equipment of $120,000, reduction in personnel, and the reduction in operating expenses as a result of the elimination of lab activities.

General and administrative expenses increased 13%, or $152,000, to $1.3 million for the six months ended June 30, 2011, compared to approximately $1.2 million for the same period in 2010, primarily due to recognition of $61,000 in accelerated depreciation expense as a result of the reduction in the term of our headquarters lease. In addition, legal expenses increased $48,000.

Other income increased $101,000 to $94,000 for the six months ended June 30, 2011, compared to an expense of $7,000 for the comparable period in 2010. This increase is due to a change of $90,000 in unrealized gain on fair value of warrant to purchase common stock for the six months ended June 30, 2011 as compared to the $7,000 unrealized loss for the six months ended June 30, 2010.

Net loss increased 15%, or $229,000, to $1.8 million for the six months ended June 30, 2011, compared to $1.5 million for the same period in 2010. The increase in net loss reflects higher general and administrative expenses and lower revenues.  

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented Controlled Delivery Technology (CDT) platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the advancement of the Company's nutritional business, the use of proceeds from a financing transaction, and anticipated orders of its nutritional products.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future.  A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to manage expenses, generate revenue and/or unanticipated changes in the timing, amount or terms of orders for its nutritional products.  Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.SCOLR Pharma, Inc.CONDENSED BALANCE SHEETS(In thousands, except par values and number of shares)June 30,
2011
(Unaudited)December 31,
2010(1)ASSETSCurrent AssetsCash and cash equivalents

$  1,186

$  1,891Accounts receivable

8

103Inventory

320

324Prepaid expenses

488

270Current portion of deferred financing costs

172

-Total current assets

2,174

2,588Property and Equipment - net of accumulated depreciation of $212 and $217, respectively

181

327Intangible assets - net of accumulated amortization of $409 and $354, respectively

651

686Deferred financing costs

172

-Restricted cash

-

257$  3,178

$  3,858LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable

$  149

$  145Accrued liabilities

267

307Interest payable

3

-Deferred revenue

-

56Fair value of warrant

53

150Total current liabilities

472

658Deferred rent

-

159Long-term portion convertible debentures – net of discount

478

-Total liabilities

950

817Commitments and Contingencies

-

-Stockholders' EquityPreferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding

-

-Common stock, authorized 150,000,000 and 100,000,000 shares, $.001 par value, 49,816,073 and 49,816,073 issued and outstanding as of June 30, 2011, and December 31, 2010

49

49Additional paid-in capital

77,989

77,041Accumulated deficit

(75,810)

(74,049)Total stockholders' equity

2,228

3,041$  3,178

$  3,858(1) restated SCOLR Pharma, Inc.UNAUDITED CONDENSED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)Three months endedJune 30,Six months endedJune 30,20112010(1)20112010(1)RevenuesLicensing fees$

-$

100$

-$

125Royalty income812374264Research and development --118-   Total revenues8223192389Operating expensesMarketing and selling5386178145Research and development(103)256544596General and administrative5855721,3251,173Total operating expenses5359142,0471,914Loss from operations(527)(691)(1,855)(1,525)Other income (expense)Interest income--11Interest expense(5)-(5)-Unrealized gain (loss) on fair value of warrant(8)225977Other1(15)1(15)Total other income (expense)(12)21094(7)Net loss$

(539)$

(481)$

(1,761)$

(1,532)Net loss per share, basic and diluted$

(0.01)$

(0.01)$

(0.04)$

(0.03)Shares used in computing basic and diluted net loss per share49,81649,68449,81646,430(1) restated Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050


'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
2. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
3. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
4. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
5. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
6. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
7. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
8. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
9. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
10. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
(Date:2/5/2016)... ... February 05, 2016 , ... Susan Polk Health Insurance ... Obispo users can expect to see in 2016. To view the report, see below, ... will directly impact many San Luis Obispo seniors who rely on Medicare health insurance ...
(Date:2/4/2016)... , ... February 04, 2016 , ... According to a ... advised to see their dentist once every six months for a cleaning and checkup, ... , Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental ...
Breaking Medicine News(10 mins):